The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

L H Cavallari¹, A L Beitelshees², K V Blake³, L G Dressler⁴, J D Duarte¹, A Elsey¹, J N Eichmeyer⁵, P E Empey⁶, J P Franciosi⁷, J K Hicks⁸, A M Holmes⁹, Ljb Jeng¹⁰, C R Lee¹¹, J J Lima³, N A Limdi¹², J Modlin⁵, A O Obeng¹³, N Petry¹⁴, V M Pratt¹⁵, T C Skaar¹⁶, S Tuteja¹⁷, D Voora¹⁸, M Wagner⁵, K W Weitzel¹, R A Wilke¹⁹, J F Peterson²⁰, J A Johnson¹

Affiliations

¹ Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
² Department of Medicine, University of Maryland, Baltimore, Maryland, USA.
³ Biomedical Research Department, Nemours Children's Specialty Care, Jacksonville, Florida, USA.
⁴ Personalized Medicine and Pharmacogenetics Program, Mission Health, Asheville, North Carolina, USA.
⁵ Department of Oncology, St. Luke's Mountain States Tumor Institute, Boise, Idaho, USA.
⁶ Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
⁷ Biomedical Research Department, Nemours Children's Specialty Care, Orlando, Florida, USA.
⁸ Division of Population Science, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
⁹ Department of Health Policy and Management, Richard M. Fairbanks School of Public Health, Indiana University - Purdue University, Indianapolis, Indiana, USA.
¹⁰ Departments of Medicine, Pathology, and Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
¹¹ Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
¹² Department of Neurology, University of Alabama, Birmingham, Alabama, USA.
¹³ Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁴ Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota, USA.
¹⁵ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹⁶ Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹⁷ Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁸ Center for Applied Genomics & Precision Medicine, Department of Medicine, Duke University, Durham, North Carolina, USA.
¹⁹ Department of Internal Medicine, University of South Dakota, Sioux Falls, South Dakota, USA.
²⁰ Departments of Biomedical Informatics and Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

PMID: 28294551
PMCID: PMC5421730
DOI: 10.1111/cts.12456

Review

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

L H Cavallari et al. Clin Transl Sci. 2017 May.

. 2017 May;10(3):143-146.

doi: 10.1111/cts.12456. Epub 2017 Mar 14.

Authors

Affiliations

¹ Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, Florida, USA.
² Department of Medicine, University of Maryland, Baltimore, Maryland, USA.
³ Biomedical Research Department, Nemours Children's Specialty Care, Jacksonville, Florida, USA.
⁴ Personalized Medicine and Pharmacogenetics Program, Mission Health, Asheville, North Carolina, USA.
⁵ Department of Oncology, St. Luke's Mountain States Tumor Institute, Boise, Idaho, USA.
⁶ Department of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
⁷ Biomedical Research Department, Nemours Children's Specialty Care, Orlando, Florida, USA.
⁸ Division of Population Science, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
⁹ Department of Health Policy and Management, Richard M. Fairbanks School of Public Health, Indiana University - Purdue University, Indianapolis, Indiana, USA.
¹⁰ Departments of Medicine, Pathology, and Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
¹¹ Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
¹² Department of Neurology, University of Alabama, Birmingham, Alabama, USA.
¹³ Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
¹⁴ Department of Pharmacy Practice, North Dakota State University, Fargo, North Dakota, USA.
¹⁵ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹⁶ Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
¹⁷ Division of Translational Medicine and Human Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁸ Center for Applied Genomics & Precision Medicine, Department of Medicine, Duke University, Durham, North Carolina, USA.
¹⁹ Department of Internal Medicine, University of South Dakota, Sioux Falls, South Dakota, USA.
²⁰ Departments of Biomedical Informatics and Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.

PMID: 28294551
PMCID: PMC5421730
DOI: 10.1111/cts.12456

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
Institutions participating in the IGNITE Pharmacogenetics Working Group. Blue dots represent funded institutions within the IGNITE Network. Yellow dots represent affiliate members.

See this image and copyright information in PMC

References

1. Relling, M.V. & Klein, T.E. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89, 464–467 (2011). - PMC - PubMed
1. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015). - PMC - PubMed
1. Weitzel, K.W. et al The IGNITE network: a model for genomic medicine implementation and research. BMC. Med. Genomics. 9, 1 (2016). - PMC - PubMed
1. Scott, S.A. et al Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317–323 (2013). - PMC - PubMed
1. Cavallari L.H. et al Prospective clinical implementation of CYP2C19‐genotype guided antiplatelet therapy after PCI: a multi‐site investigation of MACE outcomes in a real‐world setting. Circulation. 134, e711–e712 (2016).

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Molecular Biology Databases
- NIAID Data Ecosystem - Find datasets on Infectious and Immune-mediated Diseases

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

Affiliations

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

Authors

Affiliations

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Molecular Biology Databases